## Amendments to the Claims

1. (Currently amended) A compound represented by the formula (I)

$$\begin{array}{c} R^2 \\ O \\ HN \\ OH \end{array}$$

wherein R<sup>1</sup> and R<sup>2</sup> are each <u>optionally substituted</u> [[a]] lower alkyl<del>-group optionally having</del> substituents, or a salt thereof.

- **2.** (Currently amended) The compound of claim 1, wherein R<sup>2</sup> is [[a]] lower alkyl-group substituted by an aromatic hydrocarbon-group, or a salt thereof.
- 3. (Currently amended) A compound represented by the formula (I)

wherein  $R^1$  is optionally substituted [[a]] lower alkyl-group optionally having substituents,  $R^2$  is [[a]] lower alkyl-group, or a salt thereof.

- 4. (Currently amended) The compound of claim 3, wherein R<sup>2</sup> is [[a]] lower alkyl<del>-group</del> having consisting of 3 or 4 carbon atoms, or a salt thereof.
- **5.** (Currently amended) The compound of claim 4, wherein the lower alkyl-group is isopropyl or isobutyl, or a salt thereof.
- **6. (Currently amended)** The compound of claim 1, wherein R<sup>1</sup> is [[a]] <u>substituted</u> lower alkyl<del>-group having substituent(s)</del>, or a salt thereof.

- 7. (Currently amended) The compound of claim 6, wherein the substituent(s) that the lower alkyl-group has is substituted with an optionally substituted aromatic hydrocarbon-group optionally having substituents, or a salt thereof.
- 8. (Currently amended) The compound of claim 7, wherein the <u>optionally substituted</u> aromatic hydrocarbon-group is an aromatic hydrocarbon-group substituted by <u>with a group</u> substituted
- **9.** (Currently amended) The compound of claim 7, wherein the <u>optionally substituted</u> aromatic hydrocarbon-group is [[a]] phenyl-group or 2-naphthyl-group.
- 10. (Original) (2S,5S)-5-Benzyl-6-hydroxy-2-(2-methylpropyl)-3-morpholinone.

## 11-13. (Cancelled)

**14.** (Currently amended) A pharmaceutical composition comprising a compound represented by the formula (I)

wherein R<sup>1</sup> and R<sup>2</sup> are each <u>optionally substituted</u> [[a]] lower alkyl<del>-group optionally having substituents</del>, or a salt thereof and a pharmaceutically acceptable carrier.

## 15. (Cancelled)

16. (Currently amended) A method for treating-a disease in which calpain is involved cataract or retinal ischemic disorder, which comprises administering an effective amount of a compound represented by the formula (I)

wherein  $R^1$  and  $R^2$  are each <u>optionally substituted</u> [[a]] lower alkyl<del>-group optionally having substituents</del>, or a salt thereof, to a mammal in need of the treatment.

## 17. (Cancelled)

- 18. (Currently amended) The compound of claim 3, wherein R<sup>1</sup> is [[a]] <u>substituted</u> lower alkyl<del>-group having substituent(s)</del>, or a salt thereof.
- 19. (Currently amended) The compound of claim 18, wherein the substituent(s) that the lower alkyl is substituted with group has is an optionally substituted aromatic hydrocarbon-group optionally having substituents, or a salt thereof.
- 20. (Currently amended) The compound of claim 19, wherein the optionally substituted aromatic hydrocarbon-group is an aromatic hydrocarbon-group substituted with by a group substitutent selected from the group consisting of a hydroxy group hydroxyl, [[a]] lower alkoxy group, [[a]] cyclohexylmethoxy-group, [[a]] halogen-atom and [[a]] phenyl-group.
- **21.** (Currently amended) The compound of claim—20 19, wherein the optionally substituted aromatic hydrocarbon—group is [[a]] phenyl—group or 2-naphthyl—group.